News

MFDS concluded that GX-188E met the criteria for this designation after assessing the complete set of Phase II results from the clinical trial that was recently completed in

In December last year, Evaxion secured the FDA approval to advance with its Phase IIb clinical trial, where EVX-01 is given along with KEYTRUDA to patients with metastatic

The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across

The adeno-associated viral serotype rh10 (AAVrh10) gene therapy FBX-101 is delivered intravenously after hematopoetic stem cell transplant (HSCT) infusion. The designation for this lead adeno-associated virus (AAV) drug

The tocilizumab injection, BAT1806 is a recombinant humanised monoclonal antibody which has been developed to target interleukin-6 receptor (IL-6R). IL-6R specially binds to soluble and membrane-bound IL-6 receptors

Lecanemab is intended for the treatment of mild cognitive impairment (MCI) due to AD and mild AD dementia with confirmed amyloid pathology presence in the brain. The application

DS-5670 is an mRNA vaccine being developed against the novel coronavirus infectious disease (COVID-19). It is proposed to be used as a booster vaccine to prevent Covid-19. The

Myelin is an insulating material that allows proper function of neurons. It made of specialised cells of the nervous system called oligodendrocytes. This myelin sheath offers a protective

The inhaled mRNA-based therapeutic is intended for people with CF, including those with genotypes that are not responsive to approved CFTR modulators. ReCode Therapeutics CEO Shehnaaz Suliman said: